Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26724613 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2USP2LMNATSHRGLA | |
| SCHEMBL343573 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2USP2LMNATSHRGLA | |
| Acetic Acid SCHEMBL2774932 | 0.94 | GLA (0.44) | SMN1; SMN2USP2LMNATSHRGLA | |
| SCHEMBL27794175 | 0.80 | GLA (0.53) | SMN1; SMN2USP2LMNATSHRGLA | |
| SCHEMBL27794179 | 0.80 | GLA (0.53) | SMN1; SMN2USP2LMNATSHRGLA | |
| SCHEMBL28637073 | 0.79 | LMNA (0.44) | SMN1; SMN2USP2LMNATSHRGLA | |
| SCHEMBL1385739 | 0.79 | LMNA (0.44) | SMN1; SMN2USP2LMNATSHRGLA | |
| SCHEMBL1385740 | 0.79 | LMNA (0.44) | SMN1; SMN2USP2LMNATSHRGLA | |
| SCHEMBL344602 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2USP2LMNATSHRGLA | |
| SCHEMBL26724598 | 0.74 | LMNA (0.41) | SMN1; SMN2USP2LMNATSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023012819-A1 | RECOMBINANT TRANSAMINASE POLYPEPTIDES | QUANTUMZYME LLP (IN) | 2023-02-09 | — | — | WO | claimed |
| EP-2669266-B1 | Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate | DONG A ST CO LTD (KR) | 2016-02-24 | — | — | EP | disclosed |
| US-9249109-B2 | Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | disclosed |
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2015-01-22 | — | — | US | disclosed |
| EP-2415753-B1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG A PHARM CO LTD (KR) | 2014-08-27 | — | — | EP | disclosed |
| EP-2669265-A2 | Improved method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | Dong-A Pharmaceutical Co., Ltd. (KR) | 2013-12-04 | — | — | EP | disclosed |
| EP-2669266-A1 | Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate | Dong-A Pharmaceutical Co., Ltd. (KR) | 2013-12-04 | — | — | EP | disclosed |
| US-8598347-B2 | Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2013-12-03 | — | — | US | disclosed |
| EP-2415754-A2 | IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| EP-2415753-A2 | IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| EP-2142519-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | Dong-A Pharm.Co., Ltd. (KR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008130151-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | DONG-A PHARM. CO., LTD. (KR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025241-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | SMN1; SMN2 3968/4885USP2 875/4885LMNA 3276/4885 |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | SMN1; SMN2 2954/4885USP2 857/4885LMNA 3756/4885 |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | SMN1; SMN2 3968/4885USP2 875/4885LMNA 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.